Vimian Group AB (publ) Q2 2025 Earnings | 07/18/2025

About this video

Vimian Group AB (publ) reported its Q2 2025 results on July 18, 2025, showcasing double-digit revenue growth, a resilient performance across its core business segments, and continued execution on its strategy as a global animal health leader. Total revenue for the second quarter increased by 15% year-over-year to EUR 104.3 million, with organic growth of 5%. Growth was broad-based, though the MedTech segment experienced a 4% organic decline attributed to ongoing softness in the US surgery market. Adjusted EBITA rose by 3% to EUR 25.4 million, representing an adjusted EBITA margin of 24.4%, albeit below both last year’s figure (27.1%) and market expectations. Net profit after tax climbed to EUR 8.6 million, up significantly from EUR 5.1 million in Q2 2024. Earnings per share doubled to EUR 0.02. Segment Highlights: Specialty Pharma: Revenue reached an all-time high at EUR 45.3 million with organic growth of 6% and an adjusted EBITA margin of 30.0%. MedTech: Revenue climbed 32% to EUR 37.1 million on strong inorganic growth, but organic sales fell 4%. Adjusted EBITA margin contracted to 23.7%, affected by product mix and a challenging US market. Veterinary Services: Delivered 12% revenue growth to EUR 16.2 million, maintaining a solid margin of 28.7%. Diagnostics: Saw an 18% increase in revenue to EUR 5.7 million, with a margin improvement to 9.2%. Despite some margin pressure, Vimian remains well-positioned to capitalize on global trends in animal health. The company continues to invest in innovation and efficiency, supported by a balance sheet and leverage that enable acquisition-driven growth and business resilience. During the quarter, Vimian also announced a leadership transition, with CFO Carl-Johan Zetterberg Boudrie stepping in as interim CEO. Management reiterated its mid-term targets and expectation for continued growth across all core business areas, while noting that operating margins may remain subdued near-term as investments and integration headwinds persist. About Inside Ticker: For timely earnings commentary, expert financial analysis, and updates on Vimian Group AB (publ) and leaders in animal health innovation, follow Inside Ticker and visit InsideTicker.com for industry insights and real-time reports. Hashtags: #Vimian #Q22025 #Earnings #FinancialResults #AnimalHealth #Pharma #MedTech #Veterinary #Diagnostics #RevenueGrowth #EBITA #OrganicGrowth #Innovation #GlobalMarkets #Profitability #Margin #Acquisitions #Leadership #InsideTicker #Q2Results #PetHealth #EquityMarkets #BusinessUpdate #CEOUpdate #GrowthStrategy #Healthcare #InvestorUpdate #CompanyNews